

**Fiscal Year 2006 Neurofibromatosis Research Program
Reference Table of Award Mechanisms
and Submission Requirements**

Award Mechanism	Experience of Applicant	Key Mechanism Elements	Dollars Available	Submission Deadline
Clinical Trial Award Go to: <ul style="list-style-type: none"> • Summary • Program Announcement 	All levels of experience	<ul style="list-style-type: none"> • Fund Phase I or Phase II clinical trials relevant to neurofibromatosis (NF) and/or Schwannomatosis • Preclinical data required for all clinical trial proposals • Phase I or pilot clinical trial data required for Phase II clinical trial proposals • Applicants must submit a clinical protocol and associated clinical documents • Proposals must include a named study coordinator to guide the protocol through the regulatory approval process 	<ul style="list-style-type: none"> • No total dollar amount restrictions • Funding can be requested for up to 3 years for Phase I clinical trials and for up to 4 years for Phase II clinical trials 	April 25, 2006 5:00 p.m. Eastern time
Concept Award Go to: <ul style="list-style-type: none"> • Summary • Program Announcement 	All levels of experience	<ul style="list-style-type: none"> • Fund exploration of untested, high-risk questions relevant to NF and/or Schwannomatosis • Preliminary data not required • Applicant and institution names will not be provided to reviewers 	A maximum of \$67,000 in direct costs, plus indirect costs as appropriate, for a 1-year performance period	April 25, 2006 5:00 p.m. Eastern time

<p>New Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Summary • Program Announcement 	<p>Independent investigators below the Associate Professor level (or equivalent) with access to appropriate research facilities</p>	<ul style="list-style-type: none"> • Fund investigators in the early stages of their careers • Previous training or experience in NF and/or Schwannomatosis research is allowed but not required • Preliminary data not required 	<p>A maximum of \$450,000 in direct costs for up to 3 years, plus indirect costs as appropriate</p>	<p>April 25, 2006 5:00 p.m. Eastern time</p>
<p>Resource Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Summary • Program Announcement 	<p>All levels of experience</p>	<ul style="list-style-type: none"> • Fund development and validation of tools needed to advance basic research in NF and/or Schwannomatosis • Preliminary data not required • Applicants must articulate how the proposed resource addresses an unmet need in NF/Schwannomatosis research • As applicable, applicants should explain the advantages of their approach to developing the resource over standard methodologies • Proposals must include a resource distribution plan 	<p>A maximum of \$133,000 in direct costs, plus indirect costs as appropriate, for 2 years</p>	<p>April 25, 2006 5:00 p.m. Eastern time</p>
<p>Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Summary • Program Announcement 	<p>All levels of experience</p>	<ul style="list-style-type: none"> • Sponsor the development of therapeutics and tools for their evaluation in preclinical model systems of NF and/or Schwannomatosis • Formation of multidisciplinary, multi-institutional consortia is strongly encouraged 	<ul style="list-style-type: none"> • No total dollar amount restrictions • Funding can be requested for up to 3 years 	<p>April 25, 2006 5:00 p.m. Eastern time</p>

Award Mechanism	Experience of Applicant	Key Mechanism Elements	Dollars Available	Submission Deadline
<p>NF Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Summary • Program Announcement 	<p>Independent investigators at the Assistant Professor level (or equivalent) or higher</p>	<ul style="list-style-type: none"> • Support a consortium that will conceive, develop, and conduct collaborative clinical evaluations of new NF1 treatment agents or approaches • Open to any group of institutions that wishes to form an NF1 clinical consortium • Recipients of the FY05 NFRP NF Consortium Development Operations Center Award and NF Consortium Development Site Awards must jointly submit a proposal • All proposals must include at least one protocol for an NF1 <i>therapeutic</i> clinical trial and associated clinical documents • Local Institutional Review Board approvals should be in process or completed before submission • Preference will be given to protocols that have appropriate US Food and Drug Administration approval at the time the award is made 	<ul style="list-style-type: none"> • A maximum of \$2 million in direct costs for the Operations Center over a performance period of 3 years, plus indirect costs as appropriate • A maximum of \$4 million in direct costs for clinical studies over a performance period of 3 years, plus indirect costs as appropriate • Note that only one-third of the total funding allocated for this award will be from the FY06 NFRP budget; the balance is contingent upon receipt of sufficient congressional appropriations to the NFRP in FY07 and FY08 	<p><i>Required Letter of Intent is due by March 7, 2006, 5:00 pm Eastern time</i></p> <p>Proposals must be submitted and approved by August 8, 2006 5:00 p.m. Eastern time</p>